Stockscreener 앱 받기
6.15
3.89%
0.23
시간 외 거래:
6.15
전일 마감가:
$5.92
열려 있는:
$5.94
하루 거래량:
839.68K
Relative Volume:
1.26
시가총액:
$334.68M
수익:
$3.32M
순이익/손실:
$-156.76M
주가수익비율:
-2.1193
EPS:
-2.9019
순현금흐름:
$-140.13M
1주 성능:
-2.07%
1개월 성능:
-32.34%
6개월 성능:
-78.29%
1년 성능:
-40.35%
1일 변동 폭
$5.88
$6.33
1주일 범위
$5.85
$6.47
52주 변동 폭
$5.85
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
명칭
Upstream Bio Inc
전화
781-208-2466
주소
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
6.15 | 331.96M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-11-18 | 개시 | Evercore ISI | Outperform |
| 2025-10-14 | 개시 | Truist | Buy |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | Piper Sandler | Overweight |
| 2024-11-05 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 개시 | William Blair | Outperform |
모두보기
Upstream Bio Inc 주식(UPB)의 최신 뉴스
Upstream Bio presents positive Phase 2 trial data for verekitug By Investing.com - Investing.com Nigeria
Upstream Bio presents positive Phase 2 trial data for verekitug - Investing.com
Upstream Bio Reports Positive Phase 2 Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps, Achieving Clinically Meaningful Improvements in Key Symptoms - Quiver Quantitative
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements ... - Caledonian Record
Quarterly nasal polyp treatment improved symptoms for most trial patients - Stock Titan
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data showing majority of verekitug recipients achieve key improvements - Traders Union
Upstream Bio Inc. (UPB) Falls 4.39% as Shares Test Key Support LevelGamma Exposure - newsline.com
UPB Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Progress ContinuesEarnings Power Value - newsline.com
Upstream Bio Cut to Neutral From Overweight by JP Morgan - Moomoo
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
JPMorgan Downgrades Upstream Bio to Neutral From Overweight, Cuts Price Target to $8 From $35 - marketscreener.com
JPMorgan downgrades Upstream Bio stock rating on execution risks By Investing.com - Investing.com Australia
J.P. Morgan Downgrades UpStream Bio(UPB.US) to Hold Rating, Announces Target Price $8 - Moomoo
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Why Did UPB Stock Plunge 40% Today? - Stocktwits
Upstream Bio Shareholders Elect Directors, Ratify 2026 Auditor - TipRanks
Upstream Bio, Inc. leadership to share strategy at major Goldman Sachs event - Traders Union
Upstream Bio (UPB) Declines 4% as Shares Approach Key Support at $6.42Thematic ETF Flow - newsline.com
Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 - markets.businessinsider.com
Upstream Bio to present verekitug trial data at medical congress By Investing.com - Investing.com Australia
Upstream Bio to present verekitug trial data at medical congress - Investing.com
Upstream Bio, Inc. to present new Phase 2 VIBRANT trial data for verekitug at EAACI2026 - Traders Union
Upstream Bio To Showcase Additional Efficacy Data From The Phase 2 Vibrant Trial Of Verekitug In Crswnp In Oral Session At Eaaci 2026 - TradingView
Nasal polyp drug Verekitug Phase 2 data to be aired at EAACI 2026 - Stock Titan
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Spark Investor ConfidenceFinancial Data - newsline.com
Upstream Bio (UPB) Edges Lower as Shares Test Key Support ZoneFundamentals - newsline.com
Upstream Bio (UPB) price target decreased by 18.03% to 51.00 - MSN
Upstream Bio schedules fireside chat at global healthcare event - Traders Union
H.C. Wainwright Initiates UpStream Bio(UPB.US) With Buy Rating, Announces Target Price $36 - Moomoo
UPB Initiates Coverage On HC Wainwright & Co. -- Rating Set to B - GuruFocus
UPB Initiates Coverage On HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
Upstream Bio to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
H.C. Wainwright initiates Upstream Bio stock coverage with buy rating By Investing.com - Investing.com Canada
Upstream Bio: The Reset Is The Opportunity, Initiating At Buy (NASDAQ:UPB) - Seeking Alpha
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower-than-expected loss as clinical pipeline progressesEarnings Cycle Report - newsline.com
Upstream Bio (UPB) price target decreased by 10.31% to 44.37 - MSN
Upstream Bio (UPB) Edges Higher Amid Quiet Trading, Holds Above Key SupportSupply Zone - The Legal Advocate
Upstream Bio Q1 2026 Earnings: Narrower-than-Expected Loss Amid Clinical ProgressEarnings Surprise Score - The Legal Advocate
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrowed Loss Per Share as Clinical Pipeline AdvancesEPS Growth Rate - The Legal Advocate
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower Than Expected Loss Reflects Operational DisciplineAI Trading Community - Newser
Upstream Bio (UPB) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid No Revenue; Stock Edges LowerForward EPS Estimate - Newser
Upstream Bio Inc (UPB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Upstream Bio Inc 주식 (UPB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Deykin Aaron | Chief Medical Officer |
Mar 16 '26 |
Sale |
9.29 |
894 |
8,305 |
32,687 |
| Sutherland Everett Rand | Chief Executive Officer |
Mar 16 '26 |
Sale |
9.29 |
2,093 |
19,444 |
72,907 |
| Ambrose Allison | General Counsel |
Mar 16 '26 |
Sale |
9.29 |
475 |
4,413 |
16,525 |
| Houghton Adam | Chief Business Officer |
Mar 16 '26 |
Sale |
9.29 |
699 |
6,494 |
24,301 |
2.60%
0.94%
자본화:
|
볼륨(24시간):